Paul H. Johnson

Chief Scientific Officer, PhaseRx Pharmaceuticals, Inc.

Education
PhD, Biochemistry, Roswell Park Cancer Institute (SUNY)
Research interests
Delivery of siRNA and other macromolecular therapeutics